ResearcherMount Sinai HospitalNo recent work listed
Ivan M. Blasutig
Matched on ORCID iD 0000-0001-7310-2647; OpenAlex author ID A5038574343. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 24
2013: 3 papers · 2014: 1 paper · 2015: 1 paper
Papers 5
- Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. Co-author DOI 10.1371/journal.pone.0139049↗
- Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Last author DOI 10.1158/1078-0432.ccr-14-0289↗
- Strategies for discovering novel pancreatic cancer biomarkers. Last author DOI 10.1016/j.jprot.2012.09.025↗
- Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues. Co-author DOI 10.1074/mcp.m112.023507↗
- Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. Co-author DOI 10.1186/1471-2407-13-404↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Alison Chan · 4 shared papers, 2013–2014 · strength 0.18
- Paper Strategies for discovering novel pancreatic cancer biomarkers. DOI 10.1016/j.jprot.2012.09.025↗
- Paper Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. DOI 10.1158/1078-0432.ccr-14-0289↗
- Paper Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. DOI 10.1186/1471-2407-13-404↗
- Eleftherios P. Diamandis · 4 shared papers, 2013–2014 · strength 0.18
- Paper Strategies for discovering novel pancreatic cancer biomarkers. DOI 10.1016/j.jprot.2012.09.025↗
- Paper Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. DOI 10.1158/1078-0432.ccr-14-0289↗
- Paper Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. DOI 10.1186/1471-2407-13-404↗
- Randall E. Brand · 3 shared papers, 2013–2015 · strength 0.12
- Paper Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. DOI 10.1158/1078-0432.ccr-14-0289↗
- Paper Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specim… DOI 10.1371/journal.pone.0139049↗
- Paper Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of panc… DOI 10.1074/mcp.m112.023507↗
- Stefano Serra · 1 shared paper, 2014 · strength 0.05
- Subrata Sen · 1 shared paper, 2015 · strength 0.04
- Seetharaman Balasenthil · 1 shared paper, 2015 · strength 0.04
- Herbert J. Zeh · 1 shared paper, 2015 · strength 0.04
- Peter J. Allen · 1 shared paper, 2015 · strength 0.04
- Sudhir Srivastava · 1 shared paper, 2015 · strength 0.04
- Michael Anthony Hollingsworth · 1 shared paper, 2015 · strength 0.04
- Ann McNeill Killary · 1 shared paper, 2015 · strength 0.04
- Michelle Ann Anderson · 1 shared paper, 2015 · strength 0.04
- Marsha L. Frazier · 1 shared paper, 2015 · strength 0.04
- Brian B. Haab · 1 shared paper, 2015 · strength 0.04
- Karen Lynn Kaul · 1 shared paper, 2015 · strength 0.04
- Jo Ann Rinaudo · 1 shared paper, 2015 · strength 0.04
- Ying Huang · 1 shared paper, 2015 · strength 0.04
- Randy S. Haun · 1 shared paper, 2013 · strength 0.04
- Shalini Makawita · 1 shared paper, 2013 · strength 0.04
- Steve Gallinger · 1 shared paper, 2013 · strength 0.04
- Caitlin C Chrystoja · 1 shared paper, 2013 · strength 0.03
- Hari Kosanam · 1 shared paper, 2013 · strength 0.03
- Felix Rückert · 1 shared paper, 2013 · strength 0.03
- Christian P. Pilarsky · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.